Fox Business7d agobearish
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuitsJohnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
508last 24h
2497last 7d
483● bullish (7d)
253● bearish (7d)
197publishers
CNN Business8d agobearish
Johnson & Johnson offers up to $5.5 billion to settle baby powder cancer lawsuitsJohnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.
Quartz8d agobearish
Johnson & Johnson settling talc baby powder lawsuits for $5.5 billionThe deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect
CBS News8d agobearish
Johnson & Johnson offers $5.5 billion to settle talc lawsuitsJohnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.
Sky News8d agobearish
J&J offers $5.5bn to settle baby powder lawsuitsJohnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".
The Wall Street Journal8d agobearish
Johnson & Johnson Agrees to Pay Up to $5.5 Billion to Settle Talc LawsuitsThe company said it reached an agreement with firms representing plaintiffs in the outstanding talc cases to pay up to $3 billion in claim payments in 2027, with no further payments due before 2028.
Benzinga12d agobullish
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery SystemThe U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...
MedTech Dive27d agobullish
J&J wins FDA approval for dual-energy ablation catheterJohnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.